TW200925279A - Methods for recombinant manufacturing of anti-RSV antibodies - Google Patents

Methods for recombinant manufacturing of anti-RSV antibodies Download PDF

Info

Publication number
TW200925279A
TW200925279A TW097134053A TW97134053A TW200925279A TW 200925279 A TW200925279 A TW 200925279A TW 097134053 A TW097134053 A TW 097134053A TW 97134053 A TW97134053 A TW 97134053A TW 200925279 A TW200925279 A TW 200925279A
Authority
TW
Taiwan
Prior art keywords
ser
gly
val
antibody
thr
Prior art date
Application number
TW097134053A
Other languages
English (en)
Chinese (zh)
Inventor
Anne Bondgaard Tolstrup
Johan Lantto
Finn C Wiberg
Lars Soegaard Nielsen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of TW200925279A publication Critical patent/TW200925279A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW097134053A 2007-09-07 2008-09-05 Methods for recombinant manufacturing of anti-RSV antibodies TW200925279A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200701289 2007-09-07

Publications (1)

Publication Number Publication Date
TW200925279A true TW200925279A (en) 2009-06-16

Family

ID=40297785

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097134053A TW200925279A (en) 2007-09-07 2008-09-05 Methods for recombinant manufacturing of anti-RSV antibodies

Country Status (13)

Country Link
US (2) US20090137003A1 (enExample)
EP (1) EP2185590A2 (enExample)
JP (1) JP2011514139A (enExample)
KR (1) KR20100087283A (enExample)
CN (1) CN101821289A (enExample)
AU (1) AU2008295248A1 (enExample)
BR (1) BRPI0817079A2 (enExample)
CA (1) CA2695309A1 (enExample)
MX (1) MX2010002044A (enExample)
RU (1) RU2010113510A (enExample)
TW (1) TW200925279A (enExample)
WO (1) WO2009030237A2 (enExample)
ZA (1) ZA201000756B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2032701T3 (da) * 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
ATE521704T1 (de) * 2007-03-01 2011-09-15 Symphogen As Verfahren zur klonierung verwandter antikörper
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2331689A4 (en) * 2008-08-29 2012-10-31 Symphogen As METHOD OF CLONING AVIAN ORIGIN ANTIBODIES
JP5781932B2 (ja) 2008-11-03 2015-09-24 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍抗原の生物活性を特異的にブロックする抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102656189B (zh) * 2009-08-13 2014-10-08 克鲁塞尔荷兰公司 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
CN104628850B (zh) * 2009-10-06 2020-07-28 医学免疫有限公司 Rsv-特异性结合分子
JP5734988B2 (ja) * 2009-10-06 2015-06-17 メディミューン リミテド Rsv特異的結合分子
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN104131035A (zh) 2009-12-10 2014-11-05 瑞泽恩制药公司 生产重链抗体的小鼠
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP2691421B1 (en) 2011-03-31 2016-11-09 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EA201992513A1 (ru) 2012-01-09 2020-05-31 Адс Терапьютикс Са Способ лечения рака груди
AR092219A1 (es) * 2012-08-23 2015-04-08 Seattle Genetics Inc Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
JP5996707B2 (ja) * 2015-04-15 2016-09-21 メディミューン リミテド Rsv特異的結合分子
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
EP3383914A4 (en) * 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
WO2017096182A1 (en) * 2015-12-03 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
EP3529272A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3974447A3 (en) 2016-10-21 2022-09-07 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2020503844A (ja) 2016-10-21 2020-02-06 アディマブ, エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2006007850A1 (en) * 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
CA2574146C (en) * 2004-07-20 2015-06-30 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
AU2006322445B2 (en) * 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
WO2008106980A2 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
MX2009012526A (es) * 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.

Also Published As

Publication number Publication date
BRPI0817079A2 (pt) 2016-10-11
WO2009030237A2 (en) 2009-03-12
AU2008295248A1 (en) 2009-03-12
RU2010113510A (ru) 2011-10-20
US20090137003A1 (en) 2009-05-28
JP2011514139A (ja) 2011-05-06
US20120009623A1 (en) 2012-01-12
CN101821289A (zh) 2010-09-01
WO2009030237A3 (en) 2009-04-30
MX2010002044A (es) 2010-03-18
EP2185590A2 (en) 2010-05-19
ZA201000756B (en) 2010-10-27
CA2695309A1 (en) 2009-03-12
KR20100087283A (ko) 2010-08-04

Similar Documents

Publication Publication Date Title
TW200925279A (en) Methods for recombinant manufacturing of anti-RSV antibodies
AU2023203201A1 (en) Antibodies against SARS-CoV-2 and methods of using the same
TWI320716B (en) Erythropoietin receptor binding antibodies
AU2024203628A1 (en) Human immunodeficiency virus (HIV)-neutralizing antibodies
KR20080113223A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
KR20230002261A (ko) 항-sars-cov-2 중화 항체 및 이의 사용 방법
KR20090127341A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 항체
US7141653B2 (en) Human monoclonal antibodies to interleukin-5
KR101418606B1 (ko) Her-3 지향 항체 및 그 용도
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
CN101522716B (zh) 抗人il-4受体的高亲和力人抗体
CN110799540B (zh) 多特异性抗体及其制备和使用方法
CN112262156B (zh) 抗her2抗体
KR20070038556A (ko) 항-rhesus d 재조합 폴리클로날 항체 및 이의 제조방법
TW201010726A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
KR20090088936A (ko) 사람 델타 유사 리간드 4에 대한 사람 항체
TW200932268A (en) Binding molecules to the human OX40 receptor
MXPA05005160A (es) Anticuerpos monoclonales humanos contra la cd25.
AU2025203320A1 (en) Bispecific antibody and uses thereof
KR101900435B1 (ko) 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
KR20150016590A (ko) 광견병 감염의 방지 및 치료에 관한 조성물 및 방법
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
AU2020256828A1 (en) Anti-CD40 antibody and use thereof
CN116284426A (zh) 一种抗gucy2c/cd3双特异性抗体及其用途
KR20230042598A (ko) SARS-CoV-2 중화 항체 또는 그 단편